Analyst Ratings For Celldex Therapeutics (NASDAQ:CLDX)
Today, Leerink Swann lowered its price target on Celldex Therapeutics (NASDAQ:CLDX) to $3.00 per share.
Some recent analyst ratings include
- 3/7/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 12/6/2017-WBB Securities Reiterated Rating of Buy.
- 6/29/2017-Aegis Reiterated Rating of Buy.
- 6/6/2017-Cowen Reiterated Rating of Buy.
- 5/11/2017-Jefferies Group Reiterated Rating of Hold.
Recent Insider Trading Activity For Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX) has insider ownership of 4.10% and institutional ownership of 57.55%.
- On 9/2/2016 Tibor Keler, VP, bought 3,000 with an average share price of $3.32 per share and the total transaction amounting to $9,960.00.
- On 11/23/2015 Avery W. Catlin, CFO, sold 25,000 with an average share price of $18.00 per share and the total transaction amounting to $450,000.00.
- On 8/25/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $14.00 per share and the total transaction amounting to $70,000.00.
- On 8/20/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
- On 8/18/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.95 per share and the total transaction amounting to $79,750.00.
- On 8/13/2015 Anthony S Marucci, CEO, bought 5,800 with an average share price of $16.81 per share and the total transaction amounting to $97,498.00.
- On 8/13/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $16.59 per share and the total transaction amounting to $82,950.00.
Recent Trading Activity for Celldex Therapeutics (NASDAQ:CLDX)
Shares of Celldex Therapeutics closed the previous trading session at 2.78 up +0.31 12.35% with 2.4600000381469727 shares trading hands.